SEC Form 4 · accession 0001851044-26-000005
Allogene Therapeutics, Inc. · ALLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Zachary Roberts
Officer — President and CEO
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 5:51 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001737287
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1 | — | Jul 1, 2026 | A | 134,530 | A | — | — | Common Stock | 134,530 | 134,530 | D |
| Stock Option (Right to buy)F2 | $2.11 | Jul 1, 2026 | A | 476,190 | A | — | Jul 1, 2036 | Common Stock | 476,190 | 476,190 | D |
Explanation of responses
- F1Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from July 20, 2026, subject to continued service through the vesting date.
- F225% of the shares subject to the stock option shall vest on July 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.